Agios to focus on developing and commercializing innovative treatments for
genetically defined diseases and sell its
oncology business to Servier for up to $2
billion plus royalties
Agios Pharmaceuticals, Inc.,a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that it will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates, and has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company.